Advertisement

Paediatric Teratoid/Rhabdoid Tumours: Germline Deletions of Chromosome 22q11.2

  • Rachel BeddowEmail author
Chapter
Part of the Pediatric Cancer book series (PECA, volume 3)

Abstract

The highly malignant rhabdoid tumours (MRTs) in particular atypical teratoid/rhabdoid tumours (AT/RT) are generally considered to be a childhood tumour with the majority of patients presenting at younger than 5 years of age. In most cases these tumours arise from inactivation of the INI1/SMARCB1 gene due to 22q11.2 deletions. Germline alterations of INI1/SMARCB1 have been found in up to 35% of patients with rhabdoid tumours. Patients with germline alterations generally present at an earlier age and with more aggressive disease, commonly with multiple primary tumours.

The chromosomal region on 22q11 is highly susceptible to microdeletions and microduplications due to the presence of several low copy repeats (LCR) within a 9 Mb region. The proximal deletion at 22q11.2 is the most well known microdeletion syndrome in this region and gives rise to DiGeorge/Velocardiofacial syndrome (DGS/VCFs). However the lesser known distal 22q11.2 deletion syndrome, when it encompasses the INI1/SMARCB1 gene, confers a high risk of developing AT/RT or MRT. Patients diagnosed with distal 22q11.2 deletion syndrome who also have rhabdoid predisposition syndrome due to loss of INI1/SMARCB1 should undergo careful monitoring due to their increased risk of developing these type of tumours.

Keywords

Deletion Syndrome Rhabdoid Tumour Epithelioid Sarcoma Beckwith Wiedemann Syndrome Malignant Rhabdoid Tumour 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

I would like to thank my friends and colleagues at Central and Southern Regional Genetic Services for their proof reading skills and Kathryn Seally for her help with Fig. 3.1.

References

  1. Beddow RA, Smith M, Kidd A, Corbett R, Hunter AG (2011) Diagnosis of distal 22q11.2 deletion syndrome in a patient with teratoid/rhabdoid tumour. Eur J Med Genet 54:295–298PubMedCrossRefGoogle Scholar
  2. Ben-Shachar S, Ou Z, Shaw CA, Belmont JW, Patel MS, Hummel M, Amato S, Tartaglia N, Berg J, Reid SV, Lalani SR, Chinault C, Cheung SW, Lupski JR, Patel A (2008) 22q11.2 Distal deletion: a recurrent genomic disorder distinct from DiGeorge syndrome and velocardiofacial syndrome. Am J Hum Genet 82:214–221PubMedCentralPubMedCrossRefGoogle Scholar
  3. Biegel JA (2006) Molecular genetics of atypical teratoid/rhabdoid tumour. Neurosurg Focus 20:E11PubMedCrossRefGoogle Scholar
  4. Biegel JA, Rourke LB, Packer RJ, Emanuel BS (1990) Monosomy22 in rhabdoid or atypical tumours of the brain. J Neurosurg 73:710–714PubMedCrossRefGoogle Scholar
  5. Biegel JA, Zhou JY, Rorke LB, Stenstrom C, Wainwright LM, Fogelegren B (1999) Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumours. Cancer Res 59:74–79PubMedGoogle Scholar
  6. Caramel J, Quignon F, Delattre O (2008) RhoA-dependent regulation of cell migration by the tumour suppressot hSNFs/INI1. Cancer Res 68:6154–6161PubMedCrossRefGoogle Scholar
  7. Douglass EC, Valentine M, Rowe ST, Parham DM, Williams JA, Sanders JM, Houghton PJ (1990) Malignant rhabdoid tumor: a highly malignant childhood tumor with minimal karyotypic changes. Genes Chromosomes Cancer 2:210–216PubMedCrossRefGoogle Scholar
  8. Eaton KW, Tooke LS, Wainwright LM, Judkins AR, Biegel JA (2011) Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors. Pediatr Blood Cancer 56:7–15PubMedCentralPubMedCrossRefGoogle Scholar
  9. Edelmann L, Pandita RK, Spiteri E, Funke B, Goldberg R, Palanisamy N, Chaganti RS, Magenis E, Shprintzen RJ, Morrow BE (1999) A common molecular basis for rearrangement disorders on 22q11. Hum Mol Genet 8:1157–1167PubMedCrossRefGoogle Scholar
  10. Guo X, Freyer L, Morrow B, Zheng D (2011) Characterization of the past and current duplication activities in the human 22q11.2 region. BMC Genomics 12:71–87PubMedCentralPubMedCrossRefGoogle Scholar
  11. Hoot AC, Russo P, Judkins AR, Perlman EJ, Biegel JA (2004) Immunohistochemical analysis of hSNF5/INI1 distinguishes renal and extra-renal malignant rhabdoid tumours from other pediatric soft tissue tumors. Am J Surg Pathol 28:1485–1791PubMedCrossRefGoogle Scholar
  12. Jackson EM, Shaikh TH, Gururangan S, Jones MC, Malkin D, Nikkel SM, Zuppan CW, Wainwright LM, Zhang F, Biegel JA (2007) High-density single nucleotide polymorphism array analysis in patients with germline deletions of 22q11.2 and malignant rhabdoid tumour. Hum Genet 122:117–127PubMedCrossRefGoogle Scholar
  13. Janson K, Nedzi LA, David O, Schorin M, Walsh JW, Bhattacharjee M, Pridjian G, Tan L, Judkins AR, Biegel JA (2006) Predisposition to atypical teratoid/rhabdoid tumor due to an inherited INI1 mutation. Pediatr Blood Cancer 47:279–284PubMedCrossRefGoogle Scholar
  14. Lafay-Cousin L, Payne E, Strother D, Chernos J, Chan M, Bernier FP (2009) Goldenhar phenotype in a child with distal 22q11.2 deletion and intracranial atypical teratoid rhabdoid tumour. Am J Med Genet 149A:2855–2859PubMedCrossRefGoogle Scholar
  15. Lynch HT, Shurin SB, Dahms BB, Izant RJ, Lynch J, Danes BS (1983) Paravertebral malignant rhabdoid tumor in infancy. Cancer 52:290–296PubMedCrossRefGoogle Scholar
  16. McKenna ES, Sansam CG, Cho YJ, Geulich H, Evans JA, Thom CS, Moreau LA, Biegel JA, Pomeroy SL, Roberts CWM (2008) Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability. Mol Cell Biol 28:6223–6233PubMedCentralPubMedCrossRefGoogle Scholar
  17. Medjkane S, Novikov E, Verteege I, Delattre O (2004) The tumor suppressor hSNF5/INI1 modulates cell growth and actin cytoskeleton organisation. Cancer Res 64:3406–3413PubMedCrossRefGoogle Scholar
  18. Mikhail FM, Descartes M, Piotrwski A, Andersson R, Diaz de Ståhl T, Komorowski J, Bruder CE, Dumanski JP, Carroll AJ (2007) A previously unrecognised microdeletion syndrome on chromosome 22 band q11.2 encompassing the BCR gene. Am J Med Genet A 143:2178–2184CrossRefGoogle Scholar
  19. Perez E, Sullivan K (2002) Chromosome 22q11.2 Deletion syndrome (DiGeorge and velocardiofacial syndromes). Curr Opin Pediatr 14:678–683PubMedCrossRefGoogle Scholar
  20. Proust F, Laquerriere A, Costantin B, Ruchoux MM, Vannier JP, Freger P (1999) Simultaneous presentation of atypical teratoid/rhabdoid tumor in siblings. J Neuro Oncol 43:63–70CrossRefGoogle Scholar
  21. Raunch A, Pfeiffer RA, Leipold G, Singer H, Tigges M, Hofbeck MA (1999) A novel 22q11.2 Microdeletion in DiGeorge syndrome. Am J Hum Genet 64:659–667CrossRefGoogle Scholar
  22. Raunch A, Zink S, Zweier C, Thiel CT, Koch A, Rauch R, Lascorz J, Hüffmeier U, Weyand M, Singer H, Hofbeck M (2005) Systematic assessment of atypical deletions reveals genotype-phenotype correlation in 22q11.2. J Med Genet 42:871–876CrossRefGoogle Scholar
  23. Ravan JB, Tepperberg JH, Papenhausen P, Lamb AN, Hedrick J, Eash D, Ledbetter DH, Martin CL (2006) Subtelomere FISH analysis of 11 688 cases: an evaluation of the frequency and pattern of subtelomere rearrangements in individuals with developmental disabilities. J Med Genet 43:478–489CrossRefGoogle Scholar
  24. Rickert CH, Paulus W (2001) Epidemiology of central nervous system tumours in childhood and adolescence based on the new WHO classification. Childs Nerv Syst 17:503–511PubMedCrossRefGoogle Scholar
  25. Roberts CWM, Biegel JA (2009) The role of SMARCB1/INI1 in development of rhabdoid tumor. Cancer Biol Ther 8(5):412–416PubMedCentralPubMedCrossRefGoogle Scholar
  26. Rødningen OK, Prescott T, Eriksson AS, Røsby O (2008) 1.4Mb recurrent 22q11.2 distal deletion syndrome, two new cases expand the phenotype. Eur J Med Genet 51:646–650PubMedCrossRefGoogle Scholar
  27. Rousseau-Merk MF, Verteege I, Legrand I, Couturier J, Mairal A, Delattre O, Aurias A (1999) hSNF5/INI1 inactivation is mainly associated with homozygous deletions and mitotic recombination in rhabdoid tumour. Cancer Res 59:3152–3156Google Scholar
  28. Scambler PJ (2000) The 22q11 deletion syndromes. Hum Mol Genet 9:2421–2426PubMedCrossRefGoogle Scholar
  29. Sévenet N, Sheridan E, Amram D, Schneider P, Handgretinge R, Delattre O (1999) Constitutional mutations of the hSNF/INI1 gene predispose to a variety of cancers. Am J Hum Genet 65:1342–1348PubMedCentralPubMedCrossRefGoogle Scholar
  30. Shaikh TH, Kurahashi H, Emanuel BS (2001) Evolutionarily conserved low copy repeats (LCRs) in 22q11 mediate deletions, duplications, translocations and genomic instability: an update and literature review. Genet Med 3:6–13PubMedCrossRefGoogle Scholar
  31. Shaikh TH, O’Connor RJ, Pierpont ME, McGrath J, Hacker AM, Nimmakayalu M, Geiger E, Emanuel BS, Saitta SC (2007) Low copy repeats mediate distal chromosome 22q11.2 deletions: sequence analysis predicts breakpoint mechanisms. Genome Res 17:482–491PubMedCrossRefGoogle Scholar
  32. Toth G, Zraly CB, Thomson TL, Jones C, Lapetino S, Murakas J, Zhang J, Dingwall AK (2011) Congenital anomalies and rhabdoid tumor associated with 22q11 germline deletion and somatic inactivation of the SMARCB1 tumor suppressor. Genes Chromosomes Cancer 50:379–388PubMedCentralPubMedCrossRefGoogle Scholar
  33. Versteege I, Sevenet N, Lange J, Rousseau-Merck M-F, Ambros P, Handgretinger R, Aurias A, Delattre O (1998) Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394:203–206PubMedCrossRefGoogle Scholar
  34. Vries RGJ, Bezrookove V, Zuijderduijn LMP, Kia SK, Houweling A, Oruetxebarria I, Raap AK, Verrijzer CP (2005) Cancer-associated mutations in chromatin remodeler hSNF5 promote chromosomal instability by compromising the mitotic checkpoint. Genes Dev 19:665–670PubMedCrossRefGoogle Scholar
  35. Wieser R, Fritz B, Ullmann R, Müller I, Galhuber M, Storlazzi CT, Ramaswamy A, Christiansen H, Shimizu N, Rehder H (2005) Novel rearrangement of chromosome band 22q11.2 causing microdeletion syndrome-like phenotype and rhabdoid tumour of the kidney. Hum Mutat 26:78–83PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  1. 1.Central and Southern Genetic ServicesWellington HospitalWellingtonNew Zealand

Personalised recommendations